NEW YORK, February 7, 2017 /PRNewswire/ --
The cannabis market is growing rapidly in North American. According to a report from Market Research Future, the North American market size of cannabis is expected to expand at a CAGR over 33% over the period of 2016 to 2021. The report indicates that the U.S., Canada and Mexico are the major markets for cannabis, while the U.S. is the largest one, accounted for 95% of the market size of the North America cannabis market. Canada market is also expected to experience fast growth as the federal government may announce plans to make cannabis legal for recreational use across the entire country in the spring. Invictus MD Strategies Corp. (OTC: IVITF) (CSE: IMH.CN), Cannabis Sativa Inc. (OTC: CBDS), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Insys Therapeutics Inc. (NASDAQ: INSY), Cara Therapeutics Inc. (NASDAQ: CARA)
The report also indicated the factors that drive the growth: "Rapid legalizing and growing awareness about the medicinal properties of marijuana to boost the market over the forecasted period… Among the country markets in North America, The U.S. and Canada accumulate significant revenue, owing to rapid legalization in the country, increasing number of evidences in favor of marijuana possessing medicinal properties, and growing acceptance among end-users"
Invictus MD Strategies Corp. (OTC: IVITF) (CSE: IMH.CN) just announced today that, "on February 6, 2017 it had entered into a binding letter of intent ("LOI") for an option to acquire 100% (the "Option") of the outstanding shares of a Late Stage Applicant (the "OptionCo") under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") from its current shareholders (the "Vendors"). In early January 2017, OptionCo had its Pre-license inspection from Health Canada and expects to receive a license to cultivate under the ACMPR in short order.
OptionCo has built 60,000 square feet of secured perimeter for its current production facility located on 150 acres (the "Property"), which is expected to have production capacity of up to 6,000 kg per annum. OptionCo has already submitted plans for additional buildings on the Property including a 30,000 square foot facility. Assuming OptionCo receives the requisite regulatory approval to cultivate, OptionCo has future expansion plans on the 150 acre Property to establish itself as a leader in the Canadian cannabis industry.
The Option will be exercisable at the sole option of Invictus MD within 30 days after OptionCo receives its license to cultivate under the ACMPR. The exercise price of the Option will be payable as follows: (i) cash payment of $4 million CDN to the Vendors; (ii) issuing to the Vendors within 10 business days of exercising the Option, 21 million common shares of Invictus MD; and (iii) issuing to the Vendors 3 million warrants with an exercise price of $1.50 per warrant, of which: 1 million warrants will expire in 6 months following the date the Option is exercised; 1 million warrants will expire in 12 months following the date the Option is exercised, and 1 million warrants will expire in 18 months following the date the Option is exercised.
Subject to completion of satisfactory due diligence, Invictus MD intends to enter into a definitive option agreement on or before February 24, 2017.
"Once the option to acquire a 100% interest in OptionCo is exercised, along with the previously acquired interest in AB Laboratories, a licensed producer under the ACMPR, Invictus MD will have significant land holdings for cannabis cultivation in Canada to meet the significant demand. From day one, Invictus MD has viewed acquiring production capacity under the ACMPR as a key driver to increasing shareholder value", said Dan Kriznic, Chairman and CEO of Invictus MD. According to a recent report from the consulting firm Deloitte "Recreational Marijuana - Insights and Opportunities", the Canadian retail cannabis market is projected to be between $4.9 billion and $8.7 billion annually. In that same report, Deloitte further estimates that satisfying the recreational cannabis market will mean producing 600,000 kilograms of marijuana annually - far more than the existing licensed producers under the ACMPR grow for medicinal purposes.
SIGN UP to Receive More Information or alerts Directly from the Company, Invictus MD Strategies Corp. Please visit http://invictus-md.com/LP-FinBuz
Cannabis Sativa Inc. (OTCQB: CBDS) develops and promotes natural cannabis products. The Company is engaged in the research, development and licensing of natural cannabis products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The Company plans to develop, produce and market products through joint ventures with companies licensed under state regulations applicable to cannabis businesses. It holds the license for a medicinal cannabis strain called NZT, a cannabis lozenge delivery methodology, and a cannabis trauma cream formula. The Company is also developing a third strain of cannabis plant named CT22.
Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments for patients with high unmet medical needs. The company's pipeline includes patent-protected synthetic transdermal cannabinoid products, which they believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
Insys Therapeutics Inc. (NASDAQ: INSY) is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems for therapeutic molecules that improve the quality of patients' lives. Using proprietary sublingual spray technology and its capabilities to develop pharmaceutical cannabinoids, the company works to address the clinical shortcomings of existing commercial products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Cara Therapeutics Inc. (NASDAQ: CARA) a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system. Its lead product candidate includes I.V. CR845, which is in Phase III clinical trials for the treatment acute postoperative pain in adult patients, as well as completed Phase II clinical trials for the treatment of uremic pruritus disease.
Please SIGN UP NOW at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook: Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information: